Key result
Brexpiprazole potentially improves tolerability over aripiprazole via less D2 and greater 5HT receptor activity.
Why the study?
Brexpiprazole has features that both overlap and contrast with aripiprazole, necessitating a comparison of their mechanisms of action.
Comparison
Brexpiprazole vs aripiprazole
Design
Review article
Authors
Loading...
Brexpiprazole's profile versus aripiprazole may guide agent selection in schizophrenia or MDD; leaves open need for head-to-head trials.
This review discusses the overlapping and contrasting mechanistic features of brexpiprazole and aripiprazole.
Stephen M. Stahl (2016) conducted a review in Schizophrenia and major depressive disorder. Brexpiprazole vs. Aripiprazole was evaluated. Brexpiprazole has less intrinsic activity at D2 receptors and more potent actions at 5HT2A, 5HT1A, and alpha 1B receptors than aripiprazole, potentially offering improved tolerability.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: